A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Adult Participants With Chronic Diabetic Peripheral Neuropathic Pain (DPNP) /NEPTUNE-17
Latest Information Update: 29 Apr 2025
At a glance
- Drugs GSK-3858279 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Acronyms NEPTUNE-17
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 24 Apr 2025 Status changed from active, no longer recruiting to discontinued. (The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study. )
- 18 Nov 2024 Planned End Date changed from 6 Oct 2025 to 23 Jan 2025.
- 18 Nov 2024 Status changed from recruiting to active, no longer recruiting.